Vanguard Group
FOMX

Vanguard Group’s Foamix Pharmaceuticals Ltd. Ordinary Shares FOMX Stock Holding History

Vanguard Group’s Portfolio FOMX Stock Details FOMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-63,069
Closed -$412K – 4149
2016
Q1 		$412K Sell
63,069
-1,909
-3% -$12.3K ﹤0.01% 3828
2015
Q4 		$527K Buy
64,978
+2,675
+4% +$20K ﹤0.01% 3817
2015
Q3 		$457K Buy
62,303
+22,438
+56% +$229K ﹤0.01% 3874
2015
Q2 		$409K Buy
+39,865
New +$441K ﹤0.01% 3915

Other funds holding FOMX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return

Vanguard Group's FOMX Position: Q2 2016 in Review

Vanguard Group sold out of Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) in Q2 2016, closing a stake of 63,069 shares — an estimated $412K sold.

Vanguard Group first reported a position in FOMX in Q2 2015 and held it in 4 quarters. The position peaked at $527K in Q4 2015. 56 funds tracked by Wall St. Rank hold FOMX as of Q2 2016.

  • Vanguard Group reported no remaining Foamix Pharmaceuticals Ltd. Ordinary Shares position as of Q2 2016 after selling out during the quarter.
  • Vanguard Group sold 63,069 Foamix Pharmaceuticals Ltd. Ordinary Shares shares in Q2 2016, an estimated $412K.
  • Vanguard Group first reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares in Q2 2015 and held it in 4 quarters.
  • Vanguard Group's Foamix Pharmaceuticals Ltd. Ordinary Shares position peaked at $527K in Q4 2015.
  • 56 funds tracked by Wall St. Rank held Foamix Pharmaceuticals Ltd. Ordinary Shares as of Q2 2016.

Based on Vanguard Group's 13F filing for Q2 2016, filed 10 Aug 2016.